Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.

Marc YchouMichel RivoireSimon ThezenasRosine GuimbaudFrançois GhiringhelliAnne Mercier-BlasLaurent MineurEric FrancoisFaiza KhemissaMarion ChauvenetReza KianmaneshMarianne FonckPhilippe HouyauThomas AparicioMarie-Pierre GalaisFranck AudemarEric AssenatEvelyne Lopez-CrapezClaire JouffroyAntoine AdenisRené AdamOlivier Bouché

Published in: British journal of cancer (2022)

We failed to increase from 50 to 70% the R0/R1 liver-resection rate with the use of 3-CTx combined with bevacizumab or cetuximab by RAS status in CRC patients with initially unresectable liver metastases.

Keyphrases

liver metastases
clinical trial
locally advanced
wild type
open label
metastatic colorectal cancer
double blind
study protocol
phase ii
squamous cell carcinoma
radiation therapy
randomized controlled trial
phase iii
placebo controlled
klebsiella pneumoniae
mesenchymal stem cells
replacement therapy